CRISPR

CRISPR2-elovl2

ID

ZDB-CRISPR-210513-2

Name

CRISPR2-elovl2

Previous Names

None

Target

elovl2 (1)

Sequence

5' - TACCTCCTAACAATCTACCT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zf3426	elovl2

Expression

Gene expression in Wild Types + CRISPR2-elovl2

No data available

Phenotype

Phenotype resulting from CRISPR2-elovl2

No data available

Phenotype of all Fish created by or utilizing CRISPR2-elovl2

Phenotype	Fish	Conditions	Figures
muscle docosapentaenoate decreased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver lysophosphatidylethanolamine increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 2 from Sun et al., 2020
muscle docosahexaenoic acid decreased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver elovl2 expression decreased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 3 from Sun et al., 2020
liver alpha-linolenic acid increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver elovl5 expression decreased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 3 from Sun et al., 2020
liver elovl4a expression increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 3 from Sun et al., 2020
muscle icosapentaenoate increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver phosphatidylcholine increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 2 from Sun et al., 2020
liver phosphatidylethanolamine increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 2 from Sun et al., 2020
liver icosapentaenoate increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver lysophosphatidylcholine increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 2 from Sun et al., 2020
muscle alpha-linolenic acid increased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver docosahexaenoic acid decreased amount, abnormal	elovl2^{zf3426/zf3426}	standard conditions	Fig. 1 from Sun et al., 2020
liver alpha-linolenic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
liver elovl2 expression decreased amount, abnormal	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 3 from Sun et al., 2020
liver docosahexaenoic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
liver diglyceride decreased amount, abnormal	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 2 from Sun et al., 2020
liver elovl5 expression decreased amount, abnormal	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 3 from Sun et al., 2020
liver icosapentaenoate normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
liver elovl4a expression increased amount, abnormal	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 3 from Sun et al., 2020
liver linoleic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
muscle all-cis-8,11,14,17-icosatetraenoic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
liver arachidonic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
muscle alpha-linolenic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
muscle docosahexaenoic acid normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
liver monoacylglycerol decreased amount, abnormal	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 2 from Sun et al., 2020
muscle icosapentaenoate normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
liver docosapentaenoate normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020
muscle docosapentaenoate normal amount, ameliorated	elovl2^{zf3426/zf3426}; elovl5^{zf3427/zf3427}	standard conditions	Fig. 1 from Sun et al., 2020

Citations